Normal fasting plasma glucose levels and type 2 diabetes in young men.

BACKGROUND The normal fasting plasma glucose level was recently defined as less than 100 mg per deciliter (5.55 mmol per liter). Whether higher fasting plasma glucose levels within this range independently predict type 2 diabetes in young adults is unclear. METHODS We obtained blood measurements, data from physical examinations, and medical and lifestyle information from men in the Israel Defense Forces who were 26 to 45 years of age. RESULTS A total of 208 incident cases of type 2 diabetes occurred during 74,309 person-years of follow-up (from 1992 through 2004) among 13,163 subjects who had baseline fasting plasma glucose levels of less than 100 mg per deciliter. A multivariate model, adjusted for age, family history of diabetes, body-mass index, physical-activity level, smoking status, and serum triglyceride levels, revealed a progressively increased risk of type 2 diabetes in men with fasting plasma glucose levels of 87 mg per deciliter (4.83 mmol per liter) or more, as compared with those whose levels were in the bottom quintile (less than 81 mg per deciliter [4.5 mmol per liter], P for trend <0.001). In multivariate models, men with serum triglyceride levels of 150 mg per deciliter (1.69 mmol per liter) or more, combined with fasting plasma glucose levels of 91 to 99 mg per deciliter (5.05 to 5.50 mmol per liter), had a hazard ratio of 8.23 (95 percent confidence interval, 3.6 to 19.0) for diabetes, as compared with men with a combined triglyceride level of less than 150 mg per deciliter and fasting glucose levels of less than 86 mg per deciliter (4.77 mmol per liter). The joint effect of a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more and a fasting plasma glucose level of 91 to 99 mg per deciliter resulted in a hazard ratio of 8.29 (95 percent confidence interval, 3.8 to 17.8), as compared with a body-mass index of less than 25 and a fasting plasma glucose level of less than 86 mg per deciliter. CONCLUSIONS Higher fasting plasma glucose levels within the normoglycemic range constitute an independent risk factor for type 2 diabetes among young men, and such levels may help, along with body-mass index and triglyceride levels, to identify apparently healthy men at increased risk for diabetes.

[1]  J. Bryan,et al.  Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis , 2005, Nature Medicine.

[2]  J. Després,et al.  What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. , 2004, Diabetes care.

[3]  D. Tanné,et al.  Fasting Plasma Glucose and Risk of Incident Ischemic Stroke or Transient Ischemic Attacks: A Prospective Cohort Study , 2004, Stroke.

[4]  Wei Chen,et al.  Correlates of carotid artery stiffness in young adults: The Bogalusa Heart Study. , 2004, Atherosclerosis.

[5]  Y. Miyazaki,et al.  Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  S. Colagiuri,et al.  Comment , 2005, Diabetologia.

[7]  B. Monia,et al.  Role of resistin in diet-induced hepatic insulin resistance. , 2004, The Journal of clinical investigation.

[8]  R. Durbin Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance , 2004, Diabetes, obesity & metabolism.

[9]  E. Tai,et al.  Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. , 2004, Diabetes care.

[10]  L. J. Hardies,et al.  Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.

[11]  M. Laakso,et al.  Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data , 2004, Diabetologia.

[12]  J. Viikari,et al.  The 21‐year follow‐up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east–west difference , 2004, Journal of internal medicine.

[13]  K. Woo,et al.  Deleterious Impact of “High Normal” Glucose Levels and Other Metabolic Syndrome Components on Arterial Endothelial Function and Intima-Media Thickness in Apparently Healthy Chinese Subjects: The CATHAY Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Z. Bloomgarden,et al.  Type 2 diabetes in the young: the evolving epidemic. , 2004, Diabetes care.

[15]  M. Lazar,et al.  Regulation of Fasted Blood Glucose by Resistin , 2004, Science.

[16]  D. Schriger,et al.  Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? , 2004, Diabetes care.

[17]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[18]  K. Wellen,et al.  Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.

[19]  Moon-Kyu Lee,et al.  The cutoff value of fasting plasma glucose to differentiate frequencies of cardiovascular risk factors in a Korean population. , 2003, Diabetes care.

[20]  S. Genuth Lowering the criterion for impaired fasting glucose is in order. , 2003, Diabetes care.

[21]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[22]  A. D. Diez Roux,et al.  Neighborhood characteristics and components of the insulin resistance syndrome in young adults: the coronary artery risk development in young adults (CARDIA) study. , 2002, Diabetes care.

[23]  J. Shaw,et al.  Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[24]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[25]  S. Haffner,et al.  Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? , 2002, Annals of Internal Medicine.

[26]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[27]  P. Greenland,et al.  Risk Factors for Coronary Heart Disease in Men 18 to 39 Years of Age , 2001, Annals of Internal Medicine.

[28]  R. Hanson,et al.  The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. , 2000, Diabetes care.

[29]  Y. Friedlander,et al.  Fasting plasma glucose in non-diabetic elderly women predicts increased all-causes mortality and coronary heart disease risk. , 2000, Australian and New Zealand journal of medicine.

[30]  J. Shaw,et al.  Impaired fasting glucose: how low should it go? , 2000, Diabetes care.

[31]  A. Dyer,et al.  Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. , 1999, JAMA.

[32]  G. Boden Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[33]  L. Franco,et al.  The ROC Curve in the Evaluation of Fasting Capillary Blood Glucose as a Screening Test for Diabetes and IGT , 1994, Diabetes Care.

[34]  R G Shulman,et al.  Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. , 1991, Science.